Recent News

• 06.02.2026 - IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
• 05.19.2026 - IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
• 05.13.2026 - IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
• 05.12.2026 - IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
• 05.06.2026 - IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

Recent Filings

• 06.02.2026 - EX-99.1 EX-99.1
• 06.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.19.2026 - EX-99.1 EX-99.1
• 05.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 3 Initial statement of beneficial ownership of securities
• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.12.2026 - 424B5 Prospectus [Rule 424(b)(5)]